Charles River Laboratories Gross Profit 2010-2024 | CRL
Charles River Laboratories annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Charles River Laboratories gross profit for the quarter ending March 31, 2024 was $0.345B, a 8.69% decline year-over-year.
- Charles River Laboratories gross profit for the twelve months ending March 31, 2024 was $1.470B, a 2.24% decline year-over-year.
- Charles River Laboratories annual gross profit for 2023 was $1.503B, a 2.73% increase from 2022.
- Charles River Laboratories annual gross profit for 2022 was $1.463B, a 9.59% increase from 2021.
- Charles River Laboratories annual gross profit for 2021 was $1.335B, a 24.32% increase from 2020.
| Charles River Laboratories Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2023 | $1,503 |
| 2022 | $1,463 |
| 2021 | $1,335 |
| 2020 | $1,074 |
| 2019 | $958 |
| 2018 | $840 |
| 2017 | $701 |
| 2016 | $644 |
| 2015 | $531 |
| 2014 | $473 |
| 2013 | $395 |
| 2012 | $392 |
| 2011 | $402 |
| 2010 | $385 |
| 2009 | $423 |
| Charles River Laboratories Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2024-03-31 | $345 |
| 2023-12-31 | $364 |
| 2023-09-30 | $362 |
| 2023-06-30 | $399 |
| 2023-03-31 | $378 |
| 2022-12-31 | $399 |
| 2022-09-30 | $370 |
| 2022-06-30 | $357 |
| 2022-03-31 | $337 |
| 2021-12-31 | $347 |
| 2021-09-30 | $337 |
| 2021-06-30 | $342 |
| 2021-03-31 | $308 |
| 2020-12-31 | $300 |
| 2020-09-30 | $289 |
| 2020-06-30 | $232 |
| 2020-03-31 | $252 |
| 2019-12-31 | $262 |
| 2019-09-30 | $246 |
| 2019-06-30 | $238 |
| 2019-03-31 | $212 |
| 2018-12-31 | $226 |
| 2018-09-30 | $216 |
| 2018-06-30 | $216 |
| 2018-03-31 | $181 |
| 2017-12-31 | $167 |
| 2017-09-30 | $177 |
| 2017-06-30 | $185 |
| 2017-03-31 | $171 |
| 2016-12-31 | $177 |
| 2016-09-30 | $156 |
| 2016-06-30 | $170 |
| 2016-03-31 | $141 |
| 2015-12-31 | $141 |
| 2015-09-30 | $138 |
| 2015-06-30 | $133 |
| 2015-03-31 | $120 |
| 2014-12-31 | $120 |
| 2014-09-30 | $118 |
| 2014-06-30 | $126 |
| 2014-03-31 | $109 |
| 2013-12-31 | $88 |
| 2013-09-30 | $100 |
| 2013-06-30 | $103 |
| 2013-03-31 | $104 |
| 2012-12-31 | $91 |
| 2012-09-30 | $93 |
| 2012-06-30 | $104 |
| 2012-03-31 | $104 |
| 2011-12-31 | $101 |
| 2011-09-30 | $93 |
| 2011-06-30 | $106 |
| 2011-03-31 | $103 |
| 2010-12-31 | $94 |
| 2010-09-30 | $91 |
| 2010-06-30 | $101 |
| 2010-03-31 | $99 |
| 2009-12-31 | $94 |
| 2009-09-30 | $107 |
| 2009-06-30 | $114 |
| 2009-03-31 | $108 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.809B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $125.903B | 15.80 |
| Cencora (COR) | United States | $47.741B | 18.61 |
| ICON (ICLR) | Ireland | $26.139B | 24.68 |
| DiDi Global (DIDIY) | China | $21.386B | 0.00 |
| Avantor (AVTR) | United States | $15.283B | 22.50 |
| CochLear (CHEOY) | Australia | $14.173B | 0.00 |
| Revvity (RVTY) | United States | $13.191B | 23.14 |
| Natera (NTRA) | United States | $13.190B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.644B | 41.60 |
| Viatris (VTRS) | United States | $12.466B | 3.73 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.137B | 0.00 |
| Solventum (SOLV) | United States | $8.860B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.681B | 0.00 |
| HealthEquity (HQY) | United States | $7.198B | 46.21 |
| Organon (OGN) | United States | $5.431B | 5.15 |
| Bausch + Lomb (BLCO) | Canada | $5.256B | 21.04 |
| Doximity (DOCS) | United States | $5.107B | 35.77 |
| PACS (PACS) | United States | $4.437B | 0.00 |
| Life Times (LTH) | United States | $3.623B | 37.96 |
| Sotera Health (SHC) | United States | $3.369B | 16.53 |
| Surgery Partners (SGRY) | United States | $3.017B | 27.60 |
| GoodRx Holdings (GDRX) | United States | $2.859B | 108.86 |
| Agilon Health (AGL) | United States | $2.677B | 0.00 |
| Progyny (PGNY) | United States | $2.487B | 42.82 |
| AMN Healthcare Services Inc (AMN) | United States | $2.029B | 8.04 |
| NovoCure (NVCR) | Jersey | $2.014B | 0.00 |
| Premier (PINC) | United States | $1.949B | 8.34 |
| BrightSpring Health Services (BTSG) | United States | $1.852B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.757B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.566B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.449B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.226B | 0.00 | |
| CareDx (CDNA) | United States | $0.749B | 0.00 |
| Embecta (EMBC) | United States | $0.722B | 4.91 |
| GeneDx Holdings (WGS) | United States | $0.717B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.695B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.680B | 7.21 |
| Auna S.A (AUNA) | Luxembourg | $0.568B | 0.00 |
| Sharecare (SHCR) | United States | $0.497B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.437B | 11.45 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.430B | 0.00 |
| Enhabit (EHAB) | United States | $0.426B | 42.50 |
| ModivCare (MODV) | United States | $0.367B | 6.87 |
| Sonida Senior Living (SNDA) | United States | $0.345B | 0.00 |
| DocGo (DCGO) | United States | $0.310B | 16.94 |
| LifeMD (LFMD) | United States | $0.288B | 0.00 |
| MultiPlan (MPLN) | United States | $0.238B | 0.00 |
| Beauty Health (SKIN) | United States | $0.223B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.212B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.204B | 0.00 |
| Biodesix (BDSX) | United States | $0.189B | 0.00 |
| So-Young (SY) | China | $0.111B | 53.49 |
| Pono Capital Two (PTWO) | United States | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.044B | 5.88 |
| Co-Diagnostics (CODX) | United States | $0.043B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.035B | 0.00 |
| Oncology Institute (TOI) | United States | $0.031B | 0.00 |
| Nutex Health (NUTX) | United States | $0.029B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.025B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.024B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.023B | 0.00 |
| OncoCyte (OCX) | United States | $0.022B | 0.00 |
| KindlyMD (KDLY) | $0.018B | 0.00 | |
| BIMI Holdings (BIMI) | United States | $0.015B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.005B | 0.00 |
| DermTech (DMTK) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.004B | 0.00 |
| OpGen (OPGN) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Assure Holdings (IONM) | United States | $0.002B | 0.00 |